Gowri Poigaialwar

Featured in: Favicon

Articles

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses - Nature Cancer

Sep 19, 2024 | nature.com | Courtney DiNardo |Divij Verma |Natalia Baran |Tianyu Cai |Veronica Guerra |Gowri Poigaialwar | +8 more

AbstractMalignancies are reliant on glutamine as an energy source and a facilitator of aberrant DNA methylation. We demonstrate preclinical synergy of telaglenastat (CB-839), a selective glutaminase inhibitor, combined with azacytidine (AZA), followed by a single-arm, open-label, phase 1b/2 study in persons with advanced myelodysplastic syndrome (MDS).

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.